These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 14522896)

  • 1. Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer.
    Polnaszek N; Kwabi-Addo B; Peterson LE; Ozen M; Greenberg NM; Ortega S; Basilico C; Ittmann M
    Cancer Res; 2003 Sep; 63(18):5754-60. PubMed ID: 14522896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
    Kaplan PJ; Mohan S; Cohen P; Foster BA; Greenberg NM
    Cancer Res; 1999 May; 59(9):2203-9. PubMed ID: 10232609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiogenesis and prostate cancer: identification of a molecular progression switch.
    Huss WJ; Hanrahan CF; Barrios RJ; Simons JW; Greenberg NM
    Cancer Res; 2001 Mar; 61(6):2736-43. PubMed ID: 11289156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer.
    Giri D; Ropiquet F; Ittmann M
    Clin Cancer Res; 1999 May; 5(5):1063-71. PubMed ID: 10353739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased fatty acid synthase expression and activity during progression of prostate cancer in the TRAMP model.
    Pflug BR; Pecher SM; Brink AW; Nelson JB; Foster BA
    Prostate; 2003 Nov; 57(3):245-54. PubMed ID: 14518031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen receptor expression induces FGF2, FGF-binding protein production, and FGF2 release in prostate carcinoma cells: role of FGF2 in growth, survival, and androgen receptor down-modulation.
    Rosini P; Bonaccorsi L; Baldi E; Chiasserini C; Forti G; De Chiara G; Lucibello M; Mongiat M; Iozzo RV; Garaci E; Cozzolino F; Torcia MG
    Prostate; 2002 Dec; 53(4):310-21. PubMed ID: 12430142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased expression of MUC18 correlates with the metastatic progression of mouse prostate adenocarcinoma in the TRAMP model.
    Wu GJ; Fu P; Chiang CF; Huss WJ; Greenberg NM; Wu MW
    J Urol; 2005 May; 173(5):1778-83. PubMed ID: 15821586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen-independent prostate cancer progression in the TRAMP model.
    Gingrich JR; Barrios RJ; Kattan MW; Nahm HS; Finegold MJ; Greenberg NM
    Cancer Res; 1997 Nov; 57(21):4687-91. PubMed ID: 9354422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer.
    Adhami VM; Siddiqui IA; Ahmad N; Gupta S; Mukhtar H
    Cancer Res; 2004 Dec; 64(23):8715-22. PubMed ID: 15574782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-invasive bioluminescent detection of prostate cancer growth and metastasis in a bigenic transgenic mouse model.
    Hsieh CL; Xie Z; Yu J; Martin WD; Datta MW; Wu GJ; Chung LW
    Prostate; 2007 May; 67(7):685-91. PubMed ID: 17342752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exogenous fibroblast growth factors maintain viability, promote proliferation, and suppress GADD45alpha and GAS6 transcript content of prostate cancer cells genetically modified to lack endogenous FGF-2.
    Shain SA
    Mol Cancer Res; 2004 Nov; 2(11):653-61. PubMed ID: 15561781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utilization of bone marrow-derived endothelial cell precursors in spontaneous prostate tumors varies with tumor grade.
    Li H; Gerald WL; Benezra R
    Cancer Res; 2004 Sep; 64(17):6137-43. PubMed ID: 15342397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential expression of specific FGF ligand and receptor isoforms during angiogenesis associated with prostate cancer progression.
    Huss WJ; Barrios RJ; Foster BA; Greenberg NM
    Prostate; 2003 Jan; 54(1):8-16. PubMed ID: 12481250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapy.
    Haram KM; Peltier HJ; Lu B; Bhasin M; Otu HH; Choy B; Regan M; Libermann TA; Latham GJ; Sanda MG; Arredouani MS
    Prostate; 2008 Oct; 68(14):1517-30. PubMed ID: 18668517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibroblast growth factor-2 mediates transforming growth factor-beta action in prostate cancer reactive stroma.
    Yang F; Strand DW; Rowley DR
    Oncogene; 2008 Jan; 27(4):450-9. PubMed ID: 17637743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia.
    Soulitzis N; Karyotis I; Delakas D; Spandidos DA
    Int J Oncol; 2006 Aug; 29(2):305-14. PubMed ID: 16820871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression pattern of mouse homolog of prostate-specific membrane antigen (FOLH1) in the transgenic adenocarcinoma of the mouse prostate model.
    Schmittgen TD; Zakrajsek BA; Hill RE; Liu Q; Reeves JJ; Axford PD; Singer MJ; Reed MW
    Prostate; 2003 Jun; 55(4):308-16. PubMed ID: 12712410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. beta1A integrin expression is required for type 1 insulin-like growth factor receptor mitogenic and transforming activities and localization to focal contacts.
    Goel HL; Breen M; Zhang J; Das I; Aznavoorian-Cheshire S; Greenberg NM; Elgavish A; Languino LR
    Cancer Res; 2005 Aug; 65(15):6692-700. PubMed ID: 16061650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of tumor angiogenesis by conditional expression of fibroblast growth factor-2 affects early but not established tumors.
    Giavazzi R; Giuliani R; Coltrini D; Bani MR; Ferri C; Sennino B; Tosatti MP; Stoppacciaro A; Presta M
    Cancer Res; 2001 Jan; 61(1):309-17. PubMed ID: 11196179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model.
    Raina K; Blouin MJ; Singh RP; Majeed N; Deep G; Varghese L; Glodé LM; Greenberg NM; Hwang D; Cohen P; Pollak MN; Agarwal R
    Cancer Res; 2007 Nov; 67(22):11083-91. PubMed ID: 18006855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.